CD274 and T-cell non-Hodgkin lymphoma: Due to encouraging results in other lymphoid diseases, PD-1 blockade was investigated in T-cell lymphoma in a small number of patients, but short duration of remission and significant adverse events were observed.<h4>Case report</h4>Here, we report successful and durable remission induction for more than 2 years with nivolumab for r/r-ALCL even without any evidence of PD-L1 expression.<h4>Conclusion</h4>This report and literature review emphasizes the importance of the graft-versus-lymphoma effect and its potential pharmacological stimulators in the field of lymphoma treatment.